Patients’ Perceptions of Gene Expression Profiling in Breast Cancer Treatment Decisions
Open Access
- 1 April 2014
- journal article
- Published by MDPI AG in Current Oncology
- Vol. 21 (2) , 203-211
Abstract
Introduction: Determining the likely benefit of adjuvant chemotherapy for early-stage breast cancer patients depends on estimating baseline recurrence risk. Gene expression profile (gep) testing of tumours informs risk prediction, but evidence of its clinical utility is limited. We explored patient perceptions of gep testing and the impact of those perceptions on chemotherapy decisions. Methods: We conducted one focus group (n = 4) and individual interviews (n = 24) with patients who used gep testing, recruited through clinics at two hospitals in Ontario. Data were analyzed using content analysis and constant comparison techniques. Results: Patients’ understanding of gep testing was variable, and misapprehensions were common. Patients valued the test because it provided them with certainty amidst confusion, with options and a sense of empowerment, and with personalized, authoritative information. They commonly believed that the test was better and fundamentally different from other clinical tests, attributing to it unique power and truth-value. This kind of “magical thinking” was derived from an amplified perception of the test’s validity and patients’ need for reassurance about their treatment choices. Despite misperceptions or magical thinking, gep was widely considered to be the deciding factor in treatment decisions. Conclusions: Patients tend to overestimate the truth-value of gep testing based on misperceptions of its validity. Our results identify a need to better support patient understanding of the test and its limitations. Findings illustrate the deep emotional investment patients make in gep test results and the impact of that investment on their treatment decisions.Keywords
This publication has 24 references indexed in Scilit:
- Women's experiences with genomic testing for breast cancer recurrence riskCancer, 2010
- Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment SelectionJournal of Clinical Oncology, 2010
- The influence of a Gene expression profile on breast cancer decisionsJournal of Surgical Oncology, 2009
- Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?The American Journal of Surgery, 2008
- When genomic and standard test results diverge: implications for breast cancer patients’ preference for chemotherapyBreast Cancer Research and Treatment, 2008
- Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical TrialsJournal of Clinical Oncology, 2008
- Impact of gene expression profiling tests on breast cancer outcomes.Evidence Report/Technology Assessment, 2008
- Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissueBreast Cancer Research and Treatment, 2006
- The HOXB13:IL17BR Expression Index Is a Prognostic Factor in Early-Stage Breast CancerJournal of Clinical Oncology, 2006
- Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast CancerJNCI: Journal of the National Cancer Institute, 2006